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The ‘‘Other Revolution’’ in Stroke Prevention
In the past, several well known clinical trials1,2 have shown
the potential benefits of carotid endarterectomy over best
medical treatment, for selected groups of patients with
carotid atheroma. The results of these trials are still cited to
set the standard of treatment even nowadays after signifi-
cant modifications in the diagnostic workup, improvements
in anaesthesiological and surgical care and after the carotid
artery stenting revolution. In recent years however, another
revolution has taken place, possibly one of the most impor-
tant advances in stroke prevention since the introduction of
anti-platelet and pressure-control medications.
There are indeed many studies in the literature regarding
the contribution of lipids to stroke risk, however conclusive
evidence is still lacking. This is due, at least to some extent,
to the design ofmost of these studies that do not consider the
heterogeneity of strokes and investigate only total choles-
terol. For instance, the PSC observational study3 that fol-
lowed 450 000 subjects for 16 years, failed to find an
association between cholesterol and stroke risk, yet it should
be noted that only total cholesterol and only fatal strokes
were evaluated regardless of the aetiology (ischemic/hae-
morrhagic); actually probably only 20% of strokes are
immediately fatal and patients with non-fatal strokes are
more likely to die later frommyocardial infarction than from
another stroke. On the other hand, in the MRFIT study4 (over
350 000 men studied), that included analysis of stroke
subtypes, a clear relationship was found between serum
cholesterol and the risk of ischemic stroke. In the Hisayama
population based study5 (2351 subjects followed for 19 years)
athero-thrombotic and lacunar strokes were significantly
increased with increasing levels of LDL cholesterol. In recent
systematic reviews, HDL cholesterol was associated
inversely with stroke risk6 and evidence of a positive asso-
ciation of triglyceride levels and stroke was found.7
Amarenco and Labreuche8 recently published on
‘‘Lancet Neurology’’ an interesting meta-analysis of statins
for stroke prevention that included over 165.000 high-risk
individuals pooled from 24 randomized trials with at least
1000 patient each. The original trials were published
between 1994 and 2009; they included the major statins
such as ‘‘atorvastatin’’, ‘‘lovastatin’’, ‘‘pravastatin’’,
‘‘rosuvastatin’’, and ‘‘simvastatin’’, in combination with
other preventive strategies. The most recent JUPITER and
SEARCH trials were included in this study.1078-5884/$36 ª 2009 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2009.04.016The meta-analysis showed a consistent 18% reduction of
all strokes in patients randomized to statins. It also showed
that each 1 mmol/L (39 mg/dL) decrease in LDL cholesterol
equates to a reduction in relative risk for stroke of 21.1%
(95% CI 6.3e33.5, pZ 0.009). In secondary prevention of
non-cardioembolic stroke, intense reduction of LDL
cholesterol by statins also significantly reduced the risk of
recurrent stroke (relative risk 0.84, 0.71e0.99, pZ 0.03)
and major cardiovascular events (0.80, 0.69e0.92,
pZ 0.002). The lower the LDL cholesterol concentration,
the greater is the risk reduction for both primary and
secondary prevention of stroke.
On the other hand the incidence of fatal stroke was
reduced by 13% (3 to 27, pZ 0.10), and this did not reach
statistical significance. Statins showed a good overall safety
profile: the incidence of haemorrhagic stroke did not
increase (RR 1.03, 95% CI 0.75e1.41, pZ 0.88;), without
evidence of heterogeneity across the trials, and only two
trials (HPS, SPARCL) of secondary prevention of stroke
suggested an increased incidence of hemorrhagic stroke.
Due to the results of these two studies however, caution
was recommended when considering statin therapy in
patients with prior cerebral haemorrhage.
A different population based study was carried out in
Japan9 on 30 802 men and 60 417 women, 40e79 years of age
with no history of stroke or coronary heart disease; they
completed a baseline risk factor survey in 1993 and
mortality surveillance was performed through 2003. Persons
with LDL cholesterol 140 mg/dL had half the sex- and age-
adjusted risk of death due to intra-parenchymal haemor-
rhage of those with LDL cholesterol <80 mg/dL. LB Gold-
stein has addressed the complex relationship between
cholesterol and brain haemorrhage in an interesting edito-
rial published in the same recent issue of Circulation.10
In spite of the fragile evidence regarding the relation-
ship between cholesterol and stroke risk, several previous
studies11e13 in addition to Amarenco’s recently updated
meta-analysis8 also showed that a reduction of cholesterol
with statins is correlated with a decrease in the incidence
of stroke in selected groups of patients. Furthermore,
statins slow the progression of carotid atherosclerosis
reduce inflammation and endothelial dysfunction and
decrease the risk of thrombo-embolic brain events by
reducing the incidence of myocardial infarction.d by Elsevier Ltd. All rights reserved.
142 Editorial‘‘Carotid plaque stabilization’’ are by no means empty
words, a recent study hosted on this Journal14 showed that
intensive lipid-lowering therapy with atorvastatin adminis-
tered for 6 months in patients with carotid artery stenosis
>40% but without indication for intervention, ameliorated
carotid plaque echogenicity quantified by the Gray-Scale
Median (GSM) score which has been previously associated
with plaque vulnerability.
In most statins trials, there is much emphasis on the
outcome of major coronary events alone; therefore the
overall benefits of statin therapy are often under-
estimated. In particular it has now been shown unequivo-
cally that statins reduce the risk not just of coronary
events but also of strokes in a wide range of subjects
(including women). Making sure that patients at high risk
of any type of occlusive major vascular events achieve,
and sustain, a significant reduction in LDL cholesterol
would probably produce major clinical and public-health
advantages.8,11e13 Raising HDL cholesterol concentrations
and lowering triglyceride concentrations may also play
a role in stroke prevention and are worth further
investigation.
We are all aware that guidelines for indication of
treatment for patients with carotid atheroma still rely
largely on studies performed when 1) ultrasonography was
not very reliable and could not offer an accurate analysis of
the plaque, 2) surgery was still burdened by mortality and
morbidity rates that would nowadays be considered unac-
ceptable at most institutions, 3) carotid stenting did not
exist. At the present time however we cannot ignore the
‘‘other’’ revolution in stroke prevention: the key role of
statins in lipid management.
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